These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 10813278

  • 21. Matrix metalloproteinases MMP-3 and MMP-1 levels in sera and synovial fluids in patients with rheumatoid arthritis and osteoarthritis.
    Mahmoud RK, El-Ansary AK, El-Eishi HH, Kamal HM, El-Saeed NH.
    Ital J Biochem; 2005; 54(3-4):248-57. PubMed ID: 16688934
    [Abstract] [Full Text] [Related]

  • 22. Cardiovascular risk factors in women with and without rheumatoid arthritis.
    Solomon DH, Curhan GC, Rimm EB, Cannuscio CC, Karlson EW.
    Arthritis Rheum; 2004 Nov; 50(11):3444-9. PubMed ID: 15529391
    [Abstract] [Full Text] [Related]

  • 23. Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis.
    Charni N, Juillet F, Garnero P.
    Arthritis Rheum; 2005 Apr; 52(4):1081-90. PubMed ID: 15818703
    [Abstract] [Full Text] [Related]

  • 24. Erythrocyte sedimentation rate, C-reactive protein, or rheumatoid factor are normal at presentation in 35%-45% of patients with rheumatoid arthritis seen between 1980 and 2004: analyses from Finland and the United States.
    Sokka T, Pincus T.
    J Rheumatol; 2009 Jul; 36(7):1387-90. PubMed ID: 19411389
    [Abstract] [Full Text] [Related]

  • 25. Increased ferritin response in adult Still's disease: specificity and relationship to outcome.
    Evensen KJ, Swaak TJ, Nossent JC.
    Scand J Rheumatol; 2007 Jul; 36(2):107-10. PubMed ID: 17476616
    [Abstract] [Full Text] [Related]

  • 26. Rheumatoid factor by laser nephelometry and Waaler-Rose assay: prognostic value in patients with recent-onset rheumatoid arthritis.
    Nikolaisen C, Rekvig OP, Nossent HC.
    Scand J Rheumatol; 2005 Jul; 34(4):269-76. PubMed ID: 16195159
    [Abstract] [Full Text] [Related]

  • 27. Serum macrophage inhibitory cytokine 1 in rheumatoid arthritis: a potential marker of erosive joint destruction.
    Brown DA, Moore J, Johnen H, Smeets TJ, Bauskin AR, Kuffner T, Weedon H, Milliken ST, Tak PP, Smith MD, Breit SN.
    Arthritis Rheum; 2007 Mar; 56(3):753-64. PubMed ID: 17328047
    [Abstract] [Full Text] [Related]

  • 28. High serum cartilage oligomeric matrix protein determines the subset of patients with early-stage rheumatoid arthritis with high serum C-reactive protein, matrix metalloproteinase-3, and MRI-proven bone erosion.
    Fujikawa K, Kawakami A, Tamai M, Uetani M, Takao S, Arima K, Iwamoto N, Aramaki T, Kawashiri S, Ichinose K, Kamachi M, Nakamura H, Origuchi T, Ida H, Aoyagi K, Eguchi K.
    J Rheumatol; 2009 Jun; 36(6):1126-9. PubMed ID: 19447929
    [Abstract] [Full Text] [Related]

  • 29. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis.
    Wolbink GJ, Voskuyl AE, Lems WF, de Groot E, Nurmohamed MT, Tak PP, Dijkmans BA, Aarden L.
    Ann Rheum Dis; 2005 May; 64(5):704-7. PubMed ID: 15485995
    [Abstract] [Full Text] [Related]

  • 30. Plasma C-reactive protein and risk of colorectal cancer in a nested case-control study: Japan Public Health Center-based prospective study.
    Otani T, Iwasaki M, Sasazuki S, Inoue M, Tsugane S, Japan Public Health Center-Based Prospective Study Group.
    Cancer Epidemiol Biomarkers Prev; 2006 Apr; 15(4):690-5. PubMed ID: 16614110
    [Abstract] [Full Text] [Related]

  • 31. Serum C-reactive protein is an independent risk factor predicting cardiometabolic risk.
    Onat A, Can G, Hergenç G.
    Metabolism; 2008 Feb; 57(2):207-14. PubMed ID: 18191050
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. The role of anti-mutated citrullinated vimentin antibodies in the diagnosis of early rheumatoid arthritis.
    Liu X, Jia R, Zhao J, Li Z.
    J Rheumatol; 2009 Jun; 36(6):1136-42. PubMed ID: 19447936
    [Abstract] [Full Text] [Related]

  • 37. Socioeconomic status and risk of rheumatoid arthritis: a Danish case-control study.
    Pedersen M, Jacobsen S, Klarlund M, Frisch M.
    J Rheumatol; 2006 Jun; 33(6):1069-74. PubMed ID: 16622905
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Additive value of immunoassay-measured fibrinogen and high-sensitivity C-reactive protein levels for predicting incident cardiovascular events.
    Mora S, Rifai N, Buring JE, Ridker PM.
    Circulation; 2006 Aug 01; 114(5):381-7. PubMed ID: 16864722
    [Abstract] [Full Text] [Related]

  • 40. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis.
    De Rycke L, Verhelst X, Kruithof E, Van den Bosch F, Hoffman IE, Veys EM, De Keyser F.
    Ann Rheum Dis; 2005 Feb 01; 64(2):299-302. PubMed ID: 15166003
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.